

Review

Ebolavirus Entry: From Molecular Characterization to Drug Discovery

Cristiano Salata, Arianna Calistri, Gualtiero Alvisi, Michele Celestino, Cristina Parolin and Giorgio Palù *

Department of Molecular Medicine, University of Padova, IT-35121 Padova, Italy; cristiano.salata@unipd.it (C.S.); arianna.calistri@unipd.it (A.C.); gualtiero.alvisi@unipd.it (G.A.); michele.celestino.uni@gmail.com (M.C.); cristina.parolin@unipd.it (C.P.)

* Correspondence: giorgio.palu@unipd.it; Tel.: +39 (0)49 8272350

Abstract: Ebola Virus Disease (EVD) is one of the most lethal transmissible infections characterized by a high fatality rate, and caused by members of the *Filoviridae* family. The recent large outbreak of EVD in West Africa (2013-2016), highlighted the worldwide danger of this disease and its impact on global public health and economy. The development of highly needed anti-*Filoviridae* antivirals has been so far hampered by the shortage of tools to study their life cycle *in vitro*, and therefore screen for potential active compounds outside a biosafety level-4 (BSL-4) containment. Importantly, the development of surrogate models to *in vitro* study of *Filoviridae* entry in a BSL-2 setting, such as viral pseudotypes and Ebola virus like particles, tremendously boosted both our knowledge on viral life cycle and the identification of promising anti-*Filoviridae* compounds interfering with viral entry. In this context, the combination of such surrogate systems with large-scale small molecule compounds and haploid genetic screenings, as well as rational drug design and drug repurposing approaches will prove priceless in our quest for the development of a treatment for EVD.

Keywords: Ebolavirus; *Filoviridae*; VSV; retroviral vectors; virus like particles; pseudovirus; antivirals; small molecules; viral entry.

1. Introduction

The genus *Ebolavirus* of the *Filoviridae* family includes five species: *Bundibugyo ebolavirus*, *Reston ebolavirus*, *Sudan ebolavirus*, *Tai Forest ebolavirus*, and *Zaire ebolavirus*. Among them, the *Zaire ebolavirus*, usually called Ebola virus (EBOV), is the most dangerous and the main causative agent of human Ebola Virus Disease (EVD) outbreaks [1]. EVD is a disease of human and non-human primates that is characterized by a high fatality rate (30-90%). EBOV persists in the environment with a still unidentified animal reservoir, most likely the fruit bats, which maintains the virus in an enzootic cycle. Occasionally, EBOV can be transmitted to non-human primates and duikers in an epizootic cycle causing outbreaks with high mortality [1]. Human infection represents a sporadic event and starts in the context of a human/animal interface. Transmission is mainly due to the contact with blood or body fluids from infected humans or animals. EVD begins with nonspecific symptoms involving fever, fatigue, and muscle ache, and evolves to a severe condition associated to vomiting, diarrhea, infrequent hemorrhaging, and mental disorder leading to a comatose state and death. The convalescence phase of survivor patients lasts several months and is characterized by fatigue, joint pain as well as loss of appetite and memory. Viral RNA can be detected in specific organs, such as the testis, for more than one year after symptoms resolution [2].

Until 2014, EVD was considered a neglected disease, causing small outbreaks in remote African villages. *Filoviridae* research was focused mainly on biology aspects of viral infection or preparedness due to the potential use of EBOV as bioweapon, and was limited to few laboratories equipped with biosafety level-4 (BSL-4) facilities. However, the recent large outbreak of EVD (West Africa, 2013-

2016) characterized by 28,616 cases and 11,310 deaths, highlighted the worldwide danger of this disease and its impact on global public health and economy [3].

Thus, research on the molecular dissection of EBOV life cycle received a strong stimulus and financial support with the ultimate goal of developing effective preventive and therapeutic approaches. In this review, we summarize the current knowledge on a specific step of the EBOV life cycle, the entry process, and the compounds identified so far capable of interfering with it, as well as the molecular models used to these purposes.

2. Ebolavirus infection of target cells

EBOV is an enveloped, negative-stranded RNA virus characterized by a virion of ≈ 80 nm of diameter and a length ranging from hundreds of nanometers to micrometers. The genome encodes for seven structural proteins: the nucleoprotein (N), the virion protein (VP) 24, VP35, VP30, VP40, the glycoprotein (GP), and the RNA-dependent RNA polymerase (L) [4]. Inside the viral particle, the ribonucleoprotein complex consists of the genomic RNA encapsidated by the N, which binds to VP35, VP30 and L. The ribonucleoprotein complex interacts with the envelope, containing the GP, through the matrix protein VP40 and the minor matrix protein VP24. Viral tropism is determined by GP that allows the interaction with target cells. EBOV productively infects a broad range of cell types such as monocytes, macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes, and adrenal cortical cells [1]. Following host cell attachment (Figure 1), virus internalization occurs by macropinocytosis, a non-selective process of engulfment [5–7]. Binding to target cells is mediated by different attaching factors, i.e. C-type lectins, T-cell immunoglobulin and mucin domain 1, Tyrosine kinase receptor Axl, and Integrins [8–20]. Furthermore, it has been shown that binding efficiency is related to the activity of acid Sphingomyelinase (aSMase) and to the presence of plasma membrane sphingomyelin [21]. On the viral side, binding and entry of EBOV into target cells is mediated by the surface glycoprotein GP, a class I fusion protein. In its native state, GP is a triplet of heterodimers, each composed of a receptor binding subunit (GP1) and a fusion subunit (GP2). The GP1 and GP2 subunits originate by the cleavage within the Golgi complex of a single precursor peptide, and remain associated through a disulfide bond and non-covalent interactions [15,22]. After initial internalization (Figure 1), virus particle trafficking into the endo-lysosomal pathway ends up into late endosomes, where the low-pH-dependent cysteine proteases cathepsins B and L allow the processing of the GP1 into a 19 kDa fusogenic form [17,21,23–26], leading to exposure of the putative receptor binding domain [27]. Subsequently, the interaction between the processed GP1 and the late endosomal/lysosomal protein Neimann-Pick C1 (NPC-1) leads to GP2-dependent fusion of the viral envelope with the limiting membrane of the endosomes [28–30]. Furthermore, it has been shown that the fusion step also requires the Two-Pore Channel 2 (TPC2) activity [31], but the real role of TPC2 in viral entry is not entirely clear yet [32]. Finally, viral nucleocapsid is released into the cytoplasm leading to the transcription and replication of the viral genome, followed by the assembly and budding of the viral progeny [33]. After the infection of primary cell targets, viral progeny spreads to a variety of cell types and tissues, eventually resulting into a generalized organ failure [1].

3. Viral models for drug discovery that can be handled in BSL-2 facilities: targeting the entry step

Considering the high lethality of EBOV and the lack of prophylactic and therapeutic treatments, the virus can only be handled in laboratories with BSL-4 containment; thus worldwide, only few scientific institutions can conduct research and test potential countermeasures against the authentic virus. This is one of the main challenges for setting up studies focusing on the characterization of viral biology, pathogenesis and drug discovery. To overcome such issue, several alternative viral “surrogate” systems have been developed, which allowed to begin dissecting the EBOV entry pathway and screening programs to identify entry inhibitors under BSL-2 containment. Such systems include viral pseudotypes and Ebola virus like particles (eVLPs). In particular, many screening programs to identify new drugs have been performed by using pseudotypes, whereas the eVLP system is considered the most reliable to molecularly dissect the EBOV life cycle.




Figure 1. Schematic representation of EBOV entry. Following interaction with attachment factors (1) the virion is internalized by the macropinocytosis (2). Inside the membrane-bound vesicle, GP is cleaved by cysteine proteases to activate its fusogenic potential (3). Upon acidification of the intraluminal space, the cleaved GP is able to interact with the specific NPC1 viral receptor (4). Such event, in addition to the activity of the TPC2 calcium channel (5), triggers the fusion between the viral envelope and the endosomal/lysosomal membrane (6), leading to viral genome release followed by transcription and replication (7).

A pseudotype is a virus or a viral vector that displays the functional envelope glycoprotein of a heterologous virus, in this case the EBOV-GP, assembled into its outer wrapping, thus acquiring a new tropism. Vesicular Stomatitis Virus (VSV) and retroviruses (RVs), likely due to their mechanism of budding that is independent for the presence of the envelope glycoproteins, are particularly suitable to generate pseudotypes. On the other end, eVLPs can be generated in the presence of specific EBOV proteins, and in this case, they lack a fully infectious viral genome.

Both systems have been extensively used as surrogates of the authentic virus. Such viral models can be handled under BSL-2 conditions, thus representing a safe system to identify host factors involved in viral entry as well as to test/validate new therapeutic approaches aimed at blocking viral entry. Finally, such EBOV surrogates can be further engineered with genes encoding for reporter proteins, and used for the identification of small molecules interfering with viral entry by large scale screenings.

3.1. Viral pseudotypes

3.1.1. Recombinant vesicular stomatitis virus (VSV)

The VSV is a nonpathogenic virus belonging to the *Rhabdoviridae* family which can be handled in laboratory with BSL-2 containment and, therefore, it has been used as a model to study many aspects of negative-strand RNA viral entry and replication. VSV assembly occurs at the plasma membrane and involves budding of virions with bullet shape of 180 nm per 75 nm from the cell surface. During budding, VSV acquires an envelope consisting of a lipid bilayer derived from the plasma membrane and spike proteins consisting of trimers of the VSV glycoprotein G (VSV-G) [34]. One of the remarkable properties of VSV is that its virions are not particularly selective with respect to the type of membrane proteins that can be incorporated into the viral envelope. Such ability to incorporate heterologous glycoproteins within the envelope coupled along with that of budding in the absence of the glycoprotein G, led to the development of recombinant viruses in which the VSV-G-encoding gene was deleted (rVSV-deltaG) and replaced with a gene encoding for an unrelated envelope protein (replication competent rVSV-deltaG) [35]. A different strategy is based on the deletion of the VSV-G-encoding gene that is replaced with reporter genes, such as genes encoding for fluorescent proteins (such as the green fluorescent protein -GFP- in the rVSV-deltaG-GFP), or for the luciferase [36]. Viral stocks can be generated by providing the producer cells with the envelope glycoprotein G *in trans*, for instance by means of expressing plasmids (Figure 2). When a glycoprotein or a glycoprotein complex from heterologous viruses is transiently expressed in cells transduced with such defective recombinant viruses, pseudotyped particles are efficiently released in the supernatant. Upon transduction of susceptible cells, the rVSV-deltaG pseudotypes, with a tropism dictated by the heterologous envelope glycoprotein(s), are able to complete a single round of replication, and to express the reporter gene of choice [36]. Indeed, rVSV-deltaG pseudotypes have been widely employed in studies focused on investigating mechanisms of EBOV entry into target cells, in the screening of antiviral compound libraries, for the development of tests aimed at the identification of neutralizing antibodies, and as vaccine vectors [35–37]. Recently, Chen and co-workers reported the generation of pseudovirus infection mouse models for *in vivo* pharmacodynamics evaluation of filovirus entry inhibitors opening the possibility to easily validate data obtained by *in vitro* experiments [38].

3.1.2. Retroviral vectors (RVs)

Retroviruses are enveloped RNA viruses that replicate through a DNA intermediate. Indeed, upon viral entry into target cells, viral genome is reverse transcribed into double-stranded DNA and transported to the cell nucleus, where it is permanently integrated into chromosomal DNA [39]. Viral DNA, which is known as proviral DNA, is, then, replicated just as any other cellular gene and transferred to daughter cells. Proviral DNA is transcribed into RNA and transported to the cytoplasm, where it can be translated into structural, enzymatic and regulatory proteins. Next, new particles will be assembled that will incorporate full length genomic RNA and bud from the cell membrane [40]. After maturation triggered by the viral protease, spherical mature viral particles of around 100 nm in diameter will be able to infect new host cells. Due to their ability to integrate their genome into the chromosomes of infected cells, retrovirus derivatives have been widely used as gene therapy vectors [41]. Lentiviruses, when compared to the other retroviruses, such as the oncogenic ones, display a more complex genome and, thus, a more complex life cycle. The etiological agent of the Acquired Immunodeficiency Syndrome, the Human Immunodeficiency Virus (HIV), is the most studied and best characterized lentivirus. Differently from gammaretroviruses, HIV can efficiently infect resting and terminally differentiated cells. This feature is one of the main reason why HIV-based lentiviral vectors are currently among the most adopted vectors for gene therapy of different




Figure 2. Recovery, growth and pseudotyping of rVSV- Δ G-GFP. The system is based on a plasmid encoding the viral genome, containing a reporter gene (GFP) instead of the native gene coding for the glycoprotein G, and four plasmids providing the packaging system (matrix M, polymerase L, phosphoprotein P and G). At the beginning, cells are cotransfected with the pVSV- Δ G-GFP plasmid along with the four packaging plasmids to recover the G-complemented rVSV- Δ G-GFP. To express the viral genome for the first viral rescue, a plasmid encoding the T7 RNA polymerase is also required (not shown). This virus can be used for the generation of a pseudotyped rVSV- Δ G-GFP by transducing cells preventively transfected with a plasmid encoding for the heterologous glycoproteins. Then, the pseudotyped virus can be used to transduce target cells.




Figure 3. Schematic representation of the production of a pseudotyped retroviral vector. This system is based on a plasmid encoding for the retroviral vector (cis-acting sequences, reporter gene), and constructs expressing the packaging system factors and the heterologous envelope glycoprotein. Packaging cells are cotransfected with the different plasmids to recover pseudotyped retroviral particles in the supernatant. Pseudotyped particles can be used to transduce target cells.

human diseases [42]. The last generation of HIV LVs are highly improved in their efficiency of transgene delivery and in their safety level. Furthermore, the backbone of RVs can be easily manipulated to express internal marker genes, in order to enable the identification of transduced cells. RVs can be easily pseudotyped with various heterologous envelopes to alter their tropism (Figure 3). While the most common example is the VSV-G pseudotyped RV, many other viral glycoproteins have also been successfully used, such EBOV and Lassa virus as the one of highly pathogenic viruses. EBOV pseudotyped RVs lead to targeted transduction of specific cell types,

allowing the study of the viral entry mechanism and the screening of compound libraries with the aim of identifying compounds able to block viral entry [42].

3.2. Ebola virus like particles (eVLPs)

The above mentioned pseudotyped systems are however inherently flawed for the study of EBOV entry given the morphological differences compared to EBOV virions. Indeed, as alluded to above RV- and VSV-pseudotyped virions are either spherical or bullet shaped, respectively; remarkably different from the filamentous EBOV particles. To overcome such limitations, the Ebolavirus-like particles (eVLPs) system was developed, which allows to generate filamentous particles, closing resembling EBOV virions. Such system relies on the peculiar properties of EBOV major matrix protein VP40, a 326 amino acid protein that is abundantly expressed during infection and plays a number of critical roles in the viral life cycle. In particular, VP40 is essential for assembly and budding of viral progeny by supporting the incorporation of viral ribonucleocapsids into budding virus particles. VP40 can assemble either as a hexamer, which appears to be involved in budding, or as an octamer that functions in genome replication and RNA binding [43–45]. When expressed alone in mammalian cells, VP40 promotes the formation of virus like particles (eVLPs) resembling filamentous virions [46–48]. While VP40 alone is able to initiate budding of eVLPs, co-expressed NP and GP are incorporated into VLPs and significantly enhance their release. Only the mature forms of glycoprotein are incorporated within the eVLPs envelope, conferring to the particles the ability to infect target cells through specific EBOV receptors [49]. Thus, pseudotyped eVLPs have been used to study the pathway of viral entry and to identify viral entry inhibitors, in a more authentic context as compared to viral pseudotypes. Furthermore, VP40 can be easily engineered with fluorescent tags that can be exploited in imaging based studies or with small epitope tags that facilitate its detection. Importantly, it has been demonstrated that the N-terminal tagging (epitope tags, beta-lactamase tag, or fluorescent proteins) of VP40 does not modify its budding capacity, and that co-expression of wild type and tagged VP40 leads to equivalent incorporation of each protein into eVLPs [50–52].

One of the most suitable VLP model to study EBOV entry and its inhibition is represented by EBOV pseudotyped eVLP obtained by expressing VP40 fused in frame with the beta-lactamase enzyme. These VLPs allow an easy detection of the fusion step of the viral entry process. Indeed, it is possible to incubate the target cells with a substrate of the beta-lactamase that will lead to the development of a characteristic color once cut by the enzyme. This reaction will take place as soon as the beta-lactamase is released in the cell cytosol upon fusion of the eVLP envelope with the endosomal membrane. Thus, by setting up appropriate experiments, it is possible to adopt these VLPs to elucidate, for instance, whether a specific compound blocks viral entry before or after the fusion step, an information that might be relevant while investigating the mechanism of action of active molecules [52].

Recently, transcription- and replication-competent eVLPs (tr-eVLPs) have been developed that allow the study of almost all aspects of the viral life cycle [53]. These VLPs contain a polycistronic mini-genome that encodes for a reporter protein along with, at least, the viral proteins VP40, and GP (Figure 4). These tr-eVLPs can be continuously maintained by transferring cell culture supernatants from infected (transduced) target cells to naïve target cells [54,55]. Tr-eVLPs appear to represent the most powerful experimental system for the screening of small molecules libraries, leading to the identification of molecules that can affect different steps of the viral replication in addition to the entry one.




Figure 4. Transcription- and replication-competent eVLP (tr-eVLP). This system is based on a minigenome, encoding for a reporter gene, the viral proteins VP40, GP, and in some cases p24, co-transfected with the constructs expressing RNP proteins (N, VP35, VP30, and L). Inside the producer cells, VP40 drives the formation of eVLPs that harbor minigenome-containing nucleocapsids. These tr-eVLPs can infect (transduce) target cells and deliver the minigenome that undergoes primary transcription mediated by RNP proteins brought into the target cells within the tr-eVLPs (in the form of nucleocapsids), resulting into the expression of the reporter gene. If target cells are pre-transfected with plasmids encoding for RNPs, the minigenome is replicated and undergoes secondary transcription (with the expression of the reporter gene) mediated by RNP proteins provided *in trans* from expression constructs. Furthermore, a new progeny of infectious tr-eVLPs is produced and can be used to transduce new target cells.

4. Ebola virus entry inhibitors

The classical approach to develop an antiviral drug is based on compound affecting the functions of specific viral proteins that play a key role in viral life cycle. On the other hand, recent approaches for the development of wide range drugs are based on targeting of host functions that are essential for viral infections. In both cases, several steps of viral replication cycle can be targeted, such as the viral entry, genome transcription/replication, and particle assembly or budding. In particular, viral entry is an essential step for the establishment of the infection and thus represents an attractive target for the development of antiviral compounds. To date, many small molecules have been identified as inhibitors of EBOV entry in pre-clinical studies [56,57]. Some of these molecules are new compounds, while others are already known drugs that have been shown to block EBOV infection in drug repurposing programs [56–58]. Among the small molecules acting as EBOV entry inhibitors that have been identified in the last years, many are cationic amphiphilic drugs (CADs), a large group of chemicals characterized by a hydrophobic aromatic ring or ring system and a hydrophilic side-chain containing an ionizable amine functional group [59]. The main antiviral activity of CADs seems to be linked to their ability to interact with different cell membranes and to accumulate in acidic intracellular compartments such as late endosomes/lysosomes that represent the gateway for EBOV entry into host cells. In addition, other small molecules with different chemical structure, or antibodies and peptides, can act as EBOV entry inhibitors affecting the virus-cell attachment, the endocytic pathway or the fusion step required by EBOV for its productive internalization inside cells [56–58]. In the following sections, we report the main molecules that have been identified so far as EBOV entry inhibitors. Information about the viral models used to accomplish this goal is reported in appendix A.

4.1. Ion channel inhibitors

The antiarrhythmic drugs amiodarone, dronedarone and verapamil are ion channel blockers that have been shown to inhibit filovirus entry in cell lines and primary cells, by using a lentiviral vector pseudotyped with the EBOV or Marburg virus (MARV) glycoproteins. Interestingly, the inhibition of viral entry was effective at concentrations that are routinely reached in sera of patients treated for arrhythmia and it was confirmed by using the authentic EBOV [60,61]. Furthermore, we demonstrated that amiodarone and its main metabolite methyldiethanolamine show an additive effect improving the potential efficacy of amiodarone as an anti-EBOV compound. Time of addition experiments suggested that the entry step was targeted by amiodarone with a host-directed mechanism of action. Amiodarone seems to reduce virus binding to target cells and to slow down the progression of the viral particles along the endocytic pathway [62]. Furthermore, the drug acts by interfering with GP processing and with the fusion of the viral envelope with the endosomal membrane, blocking the virus particles inside vesicles [61]. Finally, studies with analogues of amiodarone showed that the antiviral activity is strictly correlated with the drug ability to accumulate into the endosomal compartment and to interfere with the endocytic pathway [61].

Despite these promising results *in vitro* and encouraging data from a mouse model [63], no significant clinical improvements have been reported in humans treated with amiodarone during the West African EBOV epidemic (2013–2016) [64,65]. Furthermore, it has been recently reported that amiodarone failed to protect guinea pigs from a lethal dose of EBOV, despite the confirmation of its anti-EBOV activity in different cell types [66].

Bepiridil is a calcium channel blocker that has well characterized anti-anginal properties. It has been reported that bepridil has a strong *in vitro* antiviral activity against EBOV by inhibiting a step of viral internalization before viral fusion [67]. Although bepridil may interfere with calcium-signaling required for endolysosomal fusion, it has been recently shown that it can also directly interact with the EBOV GP, by binding to a large cavity of the viral protein, thus destabilizing its prefusion conformation [68]. Interestingly, bepridil displays a significant survival benefit with a 100% survival rate for mice exposed to EBOV and treated with the drug (12 mg/kg) twice a day, beginning on the day of virus inoculation [67]. More recently, DeWald and colleague confirmed the *in vitro* antiviral activity of bepridil against MARV in Vero E6 cells and demonstrated a similar efficacy (80%–90% survival) in a murine model of MARV disease [69].

One of the latest discovered ion channel inhibitors, active against the early phases of EBOV infection is tetrandrine, a compound obtained from the plant *Stephania tetrandra*, which is currently employed in the traditional Chinese medicine. Tetrandrine blocks the two pore calcium channel protein 2 (TPC2) that has been shown to be required for the release of the EBOV genome into the target cells [31]. Remarkably, tetrandrine showed therapeutic efficacy in a mouse model, with a survival rate of roughly 50% if administrated 1 day after challenge with a lethal dose of EBOV. Despite primate studies that will be required before clinical trials in human, tetrandrine appears as a promising anti-EBOV prophylactic compound, alone or in combination with other drugs.

Finally, testing a myxobacterial natural product library, Beck and co-workers identified noricumazole A, a potassium channel inhibitor, as a new inhibitor of EBOV entry [70].

4.2. Antimicrobial agents

4.2.1. Antiparasitic drugs

Chloroquine is a drug widely used in the past in the antimalarial therapy and prophylaxis before the emergence of resistant *Plasmodium* spp strains. This drug, readily available and well tolerated, is also endowed with antiviral properties, acting at two levels: the entry step and the inflammation process.

Indeed, chloroquine is a lysosomotropic agent that increases the endosomal pH affecting the normal vesicle sorting and endosome-membrane fusion. Furthermore, chloroquine displays anti-inflammatory properties by downregulating the production of cytokines (IFN- γ and TNF- α), and the expression of TNF- α receptor [71,72]. Thus, the antiviral activity of chloroquine could be effective

towards all viruses that require an acidic pH for infection of host cells, such as EBOV, and mitigate the clinical signs due to the deleterious strong immune activation following viral infection. The anti-EBOV activity of chloroquine has been reported in several *in vitro* studies adopting different viral models and cellular targets (reviewed in [59]). Despite these promising evidences, *in vivo* studies did not fully support the efficacy of chloroquine for the treatment of EBOV infection. In fact, the encouraging results from two studies by Madrid and co-workers, showing a protective effect of chloroquine in mice infected with a mouse-adapted EBOV strain were not supported by more recent data, based on similar regimens, in mice, hamsters and the guinea pigs [63,73–75]. As well as other CADs, chloroquine may be tested for prophylactic treatment considering that it should accumulate inside host cells to display the antiviral activity.

Among drugs correlated to chloroquine, amodiaquine, hydroxychloroquine, and aminoquinoline have been shown to inhibit filovirus infection *in vitro* using a pseudotyped virus assay and measuring the replication of the authentic EBOV [73]. Although no *in vivo* experiments have been undertaken yet, a promising result was obtained by a retrospective analysis performed on patients treated in Liberia with artesunate-amodiaquine during the West Africa outbreak of EVD. In fact, these patients showed a lower risk of death from EVD than patients treated with artemether-lumefantrine. Although this observation lacks of several controls, the clinical effect of artesunate-amodiaquine treatment should be better investigated as a possible therapeutic option for patients with EVD [76].

Recently, Lee and coworkers reported that the new antimalarial drug ferroquine inhibits EBOV entry, by affecting the pH dependent viral fusion step [77].

Suramin is a drug adopted to treat the trypanosome-caused African blindness. It has been demonstrated that Suramin, as a competitive inhibitor of heparin, displays antiviral activity and inhibits Chikungunya virus and EBOV infection in cellular models. However, due to its significant side effects, Suramin should be taken into consideration as therapeutic option only for highly deadly viral infections [78].

The FDA-approved compound Emetine, used for the treatment of amoebiasis, and its structural desmethyl analog have been shown to accumulate into the endosome/lysosome compartment inhibiting EBOV infection [79].

By using a VLP-based approach, the anthelmintic drugs albendazole and mebendazole have been reported to inhibit EBOV infection [80].

4.2.2. Antibiotics and antifungal drugs

Teicoplanin, a glycopeptide antibiotic, and its derivatives potently inhibit the entry of EBOV-GP-pseudotyped viruses in various cell types [81,82]. Studies on the antiviral mechanism indicated that teicoplanin blocks EBOV entry by specifically inhibiting the activity of cathepsin L, thus avoiding the maturation of GP and the release of the viral genome into the cytoplasm [81]. The antibiotic azithromycin has been demonstrated to inhibit eVLP entry but further studies have not been performed and its mechanism of action is still largely uncharacterized [80].

Among CADs that have been proved to inhibit EBOV infection in screening experiments, there are the antifungal drugs terconazole and triparanol, formerly used as cholesterol-lowering drugs, now withdrawn due to their numerous toxic side effects [83].

4.3. Psychoactive drugs

Chlorpromazine is an anti-psychotic drug that interferes with EBOV infection [84], probably by inhibiting the internalization of virions [85].

Carette and co-workers showed that the psychoactive drug imipramine interferes with the entry of EBOV into target cells [28]. Similar effects have been reported for different psychoactive drugs, such as the antidepressant drugs sertraline, maprotiline, and trimipramine, for the anticholinergic benzotropine, as well as for the anti-histamine/antiemetic compounds promethazine, diphenhypraline, and ketotifen [67,73,80,86]. Furthermore, two old anti-histamine drugs diphenhydramine and chlorcyclizine have been identified as potential candidates for repurposing as

anti-filovirus agents. The filovirus entry inhibition is not dependent by the anti-histamine activity, but it occurs in the endosome. In fact, docking studies showed that these drugs could directly bind to the EBOV-GP [87]. Interestingly, the newer generations of anti-histamine drugs are not able to inhibit filovirus entry, suggesting that the 1st generation anti-histamines are good candidates to develop new anti-filovirus compounds by removing the unwanted histamine or muscarinic receptor interaction ability, without losing anti-filovirus efficacy [87].

Recently, a screening of a library of 1220 small molecules with predicted anti-histamine activity identified many compounds with potent inhibitory activity against EBOV infection. Data about the structure-activity relation are extremely useful to find a good scaffold representing a favorable starting point for the rapid development of anti-EBOV therapeutic compounds [88].

4.4. Selective estrogen receptor modulators

Drug repurposing screenings showed that a number of selective estrogen receptor modulators (SERMs), such as toremifene and clomiphene, are active against EBOV, inhibiting a late stage of viral entry into target cells [83,89]. Intriguingly, such activity is independent from the expression of estrogen receptors, suggesting the involvement of an alternative mode of action [89]. Although the mechanism remains elusive, preliminary experimental data suggest that SERMs could interfere with the fusion of the viral envelope with the endosomal limiting membrane. Accordingly, it has been shown that toremifene directly interacts with the EBOV GP, triggering the premature release of the GP2 subunit, thus preventing the fusion process [90]. Moreover, Fan and colleagues reported that SERMs reduce the levels of cellular sphingosine with following increase of calcium inside the endosomes associated with the accumulation of eVLP into TPC2⁺ endosomes. Furthermore, these compounds inhibit lentiviral vector pseudotyped with EBOV GP ability to transduce target cells [91].

However, such encouraging *in vitro* results were not conclusively supported by animal studies in mice. Only one out of two studies conducted on clomiphene showed effective protection of mice, while in the case the toremifene protection was obtained only in 50% of the treated animals [63,73]. More investigations are required, in particular by using different animal models.

This is particularly important since clomiphene accumulates in the eye and in the male reproductive tract, sites of EBOV persistence in patients who recovered from the infection, and therefore it could potentially act also on EBOV “reservoirs”, thus reducing the risk of viral spread [92].

4.5. Protein kinase inhibitors

Protein kinases are involved in many cellular pathways and their dysregulation is associated to diseases as cancer. Indeed, inhibitors of protein kinases have been developed and approved as anticancer drugs. Interestingly, some of them inhibit the infection of many viruses, EBOV included, by affecting several steps of viral replication cycle, i.e. entry, assembly and release from the infected cells [80,93,94]. In particular, *in vivo* experiments demonstrated that the combination of the protein kinases inhibitors sunitinib and erlotinib can protect mice from challenges with lethal doses of EBOV [95].

An haploid genetic screening, a new approach to identify antiviral druggable targets by discovering cellular factors required for viral infection, led to the identification of the EBOV receptor NPC1 and other entry factors, such as the phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) [28]. Importantly, PIKfyve kinase activity can be pharmacologically ablated by the small molecule apilimod. *In vitro* experiments showed that apilimod inhibits infections by EBOV and MARV in primary macrophages and cell lines by interfering with viral particle trafficking and blocking virions at the level of the early endosomes [96].

Starting from the notion that EBOV activates the mitogen-activated protein kinase (MAPK) signaling during the entry step, Johnson and co-workers reported that pyridinyl imidazole inhibitors of p38 MAPK inhibits EBOV infection in cell lines and primary human monocyte-derived dendritic cells [97]. Indeed, pyridinyl imidazole inhibitors may represent leads for the development of effective drugs to treat EBOV infection.

Another potential good druggable kinase for anti-EBOV treatment is the Cyclin G Associated Kinase (GAK), a cellular regulator of the clathrin-associated host adaptor proteins AP-1 and AP-2. GAK regulates intracellular trafficking of multiple unrelated RNA viruses, both at the early and late stages of their life cycle, representing a potential target for broad-spectrum antivirals [98]. Recently, optimized Isothiazolo[4,3- b]pyridine-based inhibitors of GAK have been reported to efficiently inhibit the *in vitro* infection of EBOV, dengue and chikungunya viruses [99].

Finally, 1-Benzyl-3-cetyl-2-methylimidazolium iodide, an inhibitor of the eukaryotic elongation factor 2 kinase, significantly inhibits entry of single-cycle VSV harboring the EBOV GP. Interestingly, the antiviral activity of this compound is not due to its activity as kinase inhibitor but most likely to its lysosomotropic properties [100].

4.6. Miscellaneous compounds that inhibit EBOV entry

Screening of libraries and studies on derivatives of small molecules have identified a number of additional compounds that can inhibit EBOV entry into target cells with different mechanisms of action.

Basu and co-workers identified a benzodiazepine derivative (also named 'compound 7'), and compounds MBX2254 and MBX2270 as entry inhibitors of EBOV [101,102]. A number of compounds with anti-EBOV entry properties were also selected after a screening analysis by Anantpadama and co-workers [103]. In addition, lead compounds can be also derived by the screening of Chinese natural herbs used in the traditional medicine [104,105].

Iminodyn 17 is an inhibitor of the GTPase activity of dynamins, a class of proteins involved in the scission of newly formed membrane vesicles, which can block EBOV entry. Nobiletin and ML9 were reported to affect the trafficking of viral particles by targeting the PI3K-Akt pathway and the myosin light chain kinase activity, respectively [77].

Retro-2 is a small molecule effective against a range of bacteria, toxins, and viruses both *in vitro* and *in vivo*. The derivatives retro-2.1 and compound 25 have been showed to be more effective than the original molecule and to efficiently inhibit EBOV infection *in vitro* [106]. VLPs and pseudotyped virus based experiments indicated that these compounds block EBOV infection at a final step of viral entry [106].

At the level of late endosomes, EBOV infection can be blocked by dyphyllin derivatives, that inhibit the vacuolar (H⁺)-ATPase avoiding endosome acidification [107]. The use of cysteine cathepsin inhibitors as anti-EBOV agents have also been proposed [108]. Accordingly, a recent study showed that the inhibitors of cathepsin-L, N-acetyl-L-leucyl-L-leucyl-L methional and calpeptin, block infection of a pseudotyped virus [77].

Recently, Cui and co-workers reported that diaryl-quinoline compounds are also active as entry inhibitors of EBOV [109].

The inhibition of the fusion between the EBOV envelope and the endosomal membrane can be accomplished by adopting specific peptides. The C-peptide is a synthetic peptide that corresponds to the C-terminal heptad repeat of the transmembrane subunit GP2 required for the fusion. It has been shown that the C-peptide, combined with the arginine-rich sequence of the Tat protein of HIV to improve cellular uptake, is efficiently delivered inside the endosomes and blocks EBOV infection by interfering with a membrane fusion intermediate [110]. Recently, Li and co-workers reported that Pep-3.3, a novel cyclo-peptide developed by computational approaches as able to bind to cleavage-primed EBOV GP, exhibited specific inhibitory activity against the GP-pseudotyped VSV infection [111].

U18666A is one of the typical CAD prototypes. U18666A is a cholesterol synthesis and transport inhibitor widely used in the field of lipid research and its efficacy has been tested against important human pathogens, including EBOV [28,29,59,83]. In particular, U18666A has been employed for the identification of the EBOV-intracellular receptor NPC-1 [28,29]. Although U18666A can directly interact with NPC-1, its activity seems to be due to the pleiotropic effect on the LE/Lys system [59].

5. Conclusions

The continuous re-emergence of EVD outbreaks in Africa with the potential risk of expansion of epidemics in other continents, as well as the possibility to use EBOV as bioweapon, makes the development of effective antivirals one of the top public health priorities. The development of BSL-2 restricted systems to study the entry of highly pathogenic viruses outside the BSL-4 facilities simultaneously boosted both our knowledge of filovirus entry and the identification of potential, highly-needed antivirals. In particular, the optimization of screening protocols in miniaturized scale allows to quickly and easily analyze large libraries of small molecules, thus providing an array of chemical structures for further modelling and structure activity relationship studies. In addition, the integration of several models allows to dissect the steps of the viral replication cycle affected by drug candidates, shedding light on the mechanism of action of potential new antivirals. In the case of compounds acting on host cell functions, as it happens when a drug repurposing is undertaken, it is also possible to evaluate if multiple cellular targets contribute to the antiviral efficacy. This information might be exploited to modify the molecules under evaluation in order to improve their antiviral activity while attenuating their potential side effects. Considering the high pathogenicity of EBOV and the ability of viruses to develop drug resistances, the research of new molecules targeting different viral or host factors should allow to obtain efficient antiviral cocktails. Finally, the intense activity of the last years on anti-filoviral research may provide benefits for other neglected infectious diseases, leading to the discovery of broad range drugs useful for the containment of outbreaks caused by other viral agents.

Funding: This research and the APC were funded by the University of Padova grant DOR-2017/18.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

Table 1. EBOV entry inhibitors and viral model systems used for their discovery

Class & Compound	Viral model	Validation with EBOV ¹	Reference
Ion channel inhibitors			
Amiodarone	RV, VSV, VLP	YES	[60–62]
Bepiridil	RV, VSV	YES	[67]
Dronedarone	RV	YES	[60]
Noricumazole A	RV, VSV	N/A	[70]
Tetrandrine	VSV	YES	[31]
Verapamil	RV	YES	[60]
Antimicrobial agents			
Albendazole	VLP	N/A	[80]
Aminoquinoline	VSV	YES	[73]
Amodiaquine	VSV	YES	[73]
Azithromycin	VLP	N/A	[80]
Chloroquine	VSV	YES	[73]
Emetine	VLP	YES	[79]
Ferroquine	VLP	N/A	[77]
Hydroxychloroquine	VSV	YES	[73]
Mebendazole	VLP	N/A	[80]
Suramin	VSV	YES	[78]
Teicoplanin	RV, VLP	N/A	[81,82]
Terconazole	RV, VSV	YES	[67,83]
Triparanol	RV, VSV	YES	[83]
Psychoactive drugs			
Benzotropine	RV	YES	[86]

Chlorpromazine	RV	YES	[84]
Chlorcyclizine	RV	YES	[87]
Diphenhydramine	RV	YES	[87]
Diphenhylypyraline	VSV	YES	[73]
Imipramine	VSV	YES	[28]
Ketotifen	VSV	YES	[73]
Maprotiline	VLP	N/A	[80]
Promethazine	RV	YES	[86]
Sertraline	RV, VSV	YES	[67]
Trimipramine	RV	YES	[86]
Selective estrogen receptor modulators			
Clomiphene	VLP, VSV	YES	[67,83,89]
Toremifene	VLP	YES	[67,89]
Protein kinase inhibitors			
Apilimod	RV, VLP	YES	[96]
Erlotinib	VSV	YES	[95]
Pyridinyl imidazole	VLP	YES	[97]
Sunitinib	VSV	YES	[95]
1-Benzyl-3-cetyl-2-methylimidazolium iodide	VSV	N/A	[100]
Miscellaneous compounds			
Aloperine derivatives	RV	N/A	[104]
Benzodiazepine derivatives	RV	YES	[101]
C-peptide	VSV	YES	[110]
Calpeptin	VLP	N/A	[77]
Cyclo-peptides	VSV	N/A	[111]
Dyphyllin derivatives	VSV	YES	[107]
Ellagic acid	RV	YES	[105]
Imynodyn 17	VLP	N/A	[77]
MBX2254/2270	RV	YES	[102]
ML9	VLP	N/A	[77]
N-acetyl-L-leucyl-L-leucyl-L-methional	VLP	N/A	[77]
Nobiletin	VLP	N/A	[77]
Retro 2 and derivatives	VLP, VSV	YES	[106]
U18666A	VSV	YES	[28,29]

¹ Validation of the antiviral activity using the authentic EBOV and/or a recombinant replication competent EBOV expressing a reporter gene.

References

1. Feldmann, H.; Geisbert, T.W. Ebola haemorrhagic fever. *Lancet* **2011**, *377*, 849–862, doi:10.1016/S0140-6736(10)60667-8.
2. Subissi, L.; Keita, M.; Mesfin, S.; Rezza, G.; Diallo, B.; Van Gucht, S.; Musa, E.O.; Yoti, Z.; Keita, S.; Djingarey, M.H.; et al. Ebola Virus Transmission Caused by Persistently Infected Survivors of the 2014–2016 Outbreak in West Africa. *J. Infect. Dis.* **2018**, *218*, S287–S291, doi:10.1093/infdis/jiy280.
3. Burk, R.; Bollinger, L.; Johnson, J.C.; Wada, J.; Radoshitzky, S.R.; Palacios, G.; Bavari, S.; Jahrling, P.B.; Kuhn, J.H. Neglected filoviruses. *FEMS Microbiol. Rev.* **2016**, *40*, 494–519, doi:10.1093/femsre/fuw010.
4. Baseler, L.; Chertow, D.S.; Johnson, K.M.; Feldmann, H.; Morens, D.M. The Pathogenesis of Ebola Virus Disease. *Annu. Rev. Pathol.* **2017**, *12*, 387–418, doi:10.1146/annurev-pathol-052016-100506.
5. Saeed, M.F.; Kolokoltsov, A.A.; Albrecht, T.; Davey, R.A. Cellular Entry of Ebola Virus Involves Uptake by a Macropinocytosis-Like Mechanism and Subsequent Trafficking through Early and Late Endosomes. *PLoS Pathog.* **2010**, *6*, e1001110, doi:10.1371/journal.ppat.1001110.
6. Nanbo, A.; Imai, M.; Watanabe, S.; Noda, T.; Takahashi, K.; Neumann, G.; Halfmann, P.; Kawaoka, Y. Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner. *PLoS Pathog.* **2010**, *6*, e1001121, doi:10.1371/journal.ppat.1001121.
7. Mulherkar, N.; Raaben, M.; de la Torre, J.C.; Whelan, S.P.; Chandran, K. The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. *Virology* **2011**, *419*, 72–83, doi:10.1016/j.virol.2011.08.009.
8. Takada, A.; Watanabe, S.; Ito, H.; Okazaki, K.; Kida, H.; Kawaoka, Y. Downregulation of β 1 Integrins by Ebola Virus Glycoprotein: Implication for Virus Entry. *Virology* **2000**, *278*, 20–26, doi:10.1006/viro.2000.0601.
9. Alvarez, C.P.; Lasala, F.; Carrillo, J.; Muñiz, O.; Corbí, A.L.; Delgado, R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. *J. Virol.* **2002**, *76*, 6841–4.
10. Usami, K.; Matsuno, K.; Igarashi, M.; Denda-Nagai, K.; Takada, A.; Irimura, T. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin. *Biochem. Biophys. Res. Commun.* **2011**, *407*, 74–78, doi:10.1016/j.bbrc.2011.02.110.
11. Kondratowicz, A.S.; Lennemann, N.J.; Sinn, P.L.; Davey, R.A.; Hunt, C.L.; Moller-Tank, S.; Meyerholz, D.K.; Rennert, P.; Mullins, R.F.; Brindley, M.; et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 8426–31, doi:10.1073/pnas.1019030108.
12. Brudner, M.; Karpel, M.; Lear, C.; Chen, L.; Yantosca, L.M.; Scully, C.; Sarraju, A.; Sokolovska, A.; Zariffard, M.R.; Eisen, D.P.; et al. Lectin-Dependent Enhancement of Ebola Virus Infection via Soluble and Transmembrane C-type Lectin Receptors. *PLoS One* **2013**, *8*, e60838, doi:10.1371/journal.pone.0060838.
13. Simmons, G.; Reeves, J.D.; Grogan, C.C.; Vandenberghe, L.H.; Baribaud, F.; Whitbeck, J.C.; Burke, E.; Buchmeier, M.J.; Soilleux, E.J.; Riley, J.L.; et al. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. *Virology* **2003**, *305*, 115–23.
14. Takada, A.; Fujioka, K.; Tsuiji, M.; Morikawa, A.; Higashi, N.; Ebihara, H.; Kobasa, D.; Feldmann, H.; Irimura, T.; Kawaoka, Y. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. *J. Virol.* **2004**, *78*, 2943–7.
15. Shimojima, M.; Ikeda, Y.; Kawaoka, Y. The mechanism of Axl-mediated Ebola virus infection. *J. Infect. Dis.* **2007**, *196 Suppl 2*, S259–63, doi:10.1086/520594.
16. Lee, J.E.; Fusco, M.L.; Hessell, A.J.; Oswald, W.B.; Burton, D.R.; Saphire, E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. *Nature* **2008**, *454*, 177–182, doi:10.1038/nature07082.
17. Dube, D.; Brecher, M.B.; Delos, S.E.; Rose, S.C.; Park, E.W.; Schornberg, K.L.; Kuhn, J.H.; White, J.M. The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. *J. Virol.* **2009**, *83*, 2883–91, doi:10.1128/JVI.01956-08.
18. Schornberg, K.L.; Shoemaker, C.J.; Dube, D.; Abshire, M.Y.; Delos, S.E.; Bouton, A.H.; White, J.M. 5-1-Integrin controls ebolavirus entry by regulating endosomal cathepsins. *Proc. Natl. Acad. Sci.* **2009**, *106*, 8003–8008, doi:10.1073/pnas.0807578106.
19. Brindley, M.A.; Hunt, C.L.; Kondratowicz, A.S.; Bowman, J.; Sinn, P.L.; McCray, P.B.; Quinn, K.; Weller, M.L.; Chiorini, J.A.; Maury, W. Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. *Virology* **2011**, *415*, 83–94, doi:10.1016/j.virol.2011.04.002.
20. Hunt, C.L.; Kolokoltsov, A.A.; Davey, R.A.; Maury, W. The Tyro3 Receptor Kinase Axl Enhances Macropinocytosis of Zaire Ebolavirus. *J. Virol.* **2011**, *85*, 334–347, doi:10.1128/JVI.01278-09.
21. Miller, M.E.; Adhikary, S.; Kolokoltsov, A.A.; Davey, R.A. Ebolavirus Requires Acid Sphingomyelinase

- Activity and Plasma Membrane Sphingomyelin for Infection. *J. Virol.* **2012**, *86*, 7473–7483, doi:10.1128/JVI.00136-12.
22. Lee, J.E.; Saphire, E.O. *Ebolavirus* glycoprotein structure and mechanism of entry. *Future Virol.* **2009**, *4*, 621–635, doi:10.2217/fvl.09.56.
23. Chandran, K.; Sullivan, N.J.; Felbor, U.; Whelan, S.P.; Cunningham, J.M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. *Science* **2005**, *308*, 1643–5, doi:10.1126/science.1110656.
24. Schornberg, K.; Matsuyama, S.; Kabsch, K.; Delos, S.; Bouton, A.; White, J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. *J. Virol.* **2006**, *80*, 4174–8, doi:10.1128/JVI.80.8.4174-4178.2006.
25. Hood, C.L.; Abraham, J.; Boyington, J.C.; Leung, K.; Kwong, P.D.; Nabel, G.J. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. *J. Virol.* **2010**, *84*, 2972–82, doi:10.1128/JVI.02151-09.
26. Brecher, M.; Schornberg, K.L.; Delos, S.E.; Fusco, M.L.; Saphire, E.O.; White, J.M. Cathepsin Cleavage Potentiates the Ebola Virus Glycoprotein To Undergo a Subsequent Fusion-Relevant Conformational Change. *J. Virol.* **2012**, *86*, 364–372, doi:10.1128/JVI.05708-11.
27. Bornholdt, Z.A.; Ndungo, E.; Fusco, M.L.; Bale, S.; Flyak, A.I.; Crowe, J.E.; Chandran, K.; Saphire, E.O. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. *MBio* **2016**, *7*, e02154-15, doi:10.1128/mBio.02154-15.
28. Carette, J.E.; Raaben, M.; Wong, A.C.; Herbert, A.S.; Obernosterer, G.; Mulherkar, N.; Kuehne, A.I.; Kranzusch, P.J.; Griffin, A.M.; Ruthel, G.; et al. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1. *Nature* **2011**, *477*, 340–343, doi:10.1038/nature10348.
29. Côté, M.; Misasi, J.; Ren, T.; Bruchez, A.; Lee, K.; Filone, C.M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K.; et al. Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection. *Nature* **2011**, *477*, 344–348, doi:10.1038/nature10380.
30. Miller, E.H.; Obernosterer, G.; Raaben, M.; Herbert, A.S.; Deffieu, M.S.; Krishnan, A.; Ndungo, E.; Sandesara, R.G.; Carette, J.E.; Kuehne, A.I.; et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. *EMBO J.* **2012**, *31*, 1947–1960, doi:10.1038/emboj.2012.53.
31. Sakurai, Y.; Kolokoltsov, A.A.; Chen, C.-C.; Tidwell, M.W.; Bauta, W.E.; Klugbauer, N.; Grimm, C.; Wahl-Schott, C.; Biel, M.; Davey, R.A. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. *Science (80-.)*. **2015**, *347*, 995–998, doi:10.1126/science.1258758.
32. Simmons, J.A.; D'Souza, R.S.; Ruas, M.; Galione, A.; Casanova, J.E.; White, J.M. *Ebolavirus* Glycoprotein Directs Fusion through NPC1+ Endolysosomes. *J. Virol.* **2016**, *90*, 605–10, doi:10.1128/JVI.01828-15.
33. White, J.M.; Schornberg, K.L. A new player in the puzzle of filovirus entry. *Nat. Rev. Microbiol.* **2012**, *10*, 317–322, doi:10.1038/nrmicro2764.
34. Coll, J.M. The glycoprotein G of rhabdoviruses. *Arch. Virol.* **1995**, *140*, 827–51.
35. Geisbert, T.W.; Feldmann, H. Recombinant Vesicular Stomatitis Virus–Based Vaccines Against Ebola and Marburg Virus Infections. *J. Infect. Dis.* **2011**, *204*, S1075–S1081, doi:10.1093/infdis/jir349.
36. Whitt, M.A. Generation of VSV pseudotypes using recombinant Δ G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. *J. Virol. Methods* **2010**, *169*, 365–374, doi:10.1016/j.jviromet.2010.08.006.
37. Whitt, M.A.; Geisbert, T.W.; Mire, C.E. Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses. In *Methods in molecular biology (Clifton, N.J.)*; 2016; Vol. 1403, pp. 295–311.
38. Chen, Q.; Tang, K.; Zhang, X.; Chen, P.; Guo, Y. Establishment of pseudovirus infection mouse models for in vivo pharmacodynamics evaluation of filovirus entry inhibitors. *Acta Pharm. Sin. B* **2018**, *8*, 200–208, doi:10.1016/j.apsb.2017.08.003.
39. Nisole, S.; Saïb, A. Early steps of retrovirus replicative cycle. *Retrovirology* **2004**, *1*, 9, doi:10.1186/1742-4690-1-9.
40. Sundquist, W.I.; Krausslich, H.-G. HIV-1 Assembly, Budding, and Maturation. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006924–a006924, doi:10.1101/cshperspect.a006924.
41. Vargas, J.E.; Chicaybam, L.; Stein, R.T.; Tanuri, A.; Delgado-Cañedo, A.; Bonamino, M.H. Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives. *J. Transl. Med.* **2016**, *14*, 288, doi:10.1186/s12967-016-1047-x.
42. Joglekar, A. V.; Sandoval, S. Pseudotyped Lentiviral Vectors: One Vector, Many Guises. *Hum. Gene Ther. Methods* **2017**, *28*, 291–301, doi:10.1089/hgtb.2017.084.
43. Ruigrok, R.W.; Schoehn, G.; Dessen, A.; Forest, E.; Volchkov, V.; Dolnik, O.; Klenk, H.D.; Weissenhorn, W. Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. *J. Mol. Biol.* **2000**, *300*, 103–12, doi:10.1006/jmbi.2000.3822.

44. Timmins, J.; Schoehn, G.; Kohlhaas, C.; Klenk, H.-D.; Ruigrok, R.W.H.; Weissenhorn, W. Oligomerization and polymerization of the filovirus matrix protein VP40. *Virology* **2003**, *312*, 359–68.
45. Bornholdt, Z.A.; Noda, T.; Abelson, D.M.; Halfmann, P.; Wood, M.R.; Kawaoka, Y.; Saphire, E.O. Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle. *Cell* **2013**, *154*, 763–774, doi:10.1016/j.cell.2013.07.015.
46. Harty, R.N.; Brown, M.E.; Wang, G.; Huibregtse, J.; Hayes, F.P. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: Implications for filovirus budding. *Proc. Natl. Acad. Sci.* **2000**, *97*, 13871–13876, doi:10.1073/pnas.250277297.
47. Jasenosky, L.D.; Neumann, G.; Lukashevich, I.; Kawaoka, Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. *J. Virol.* **2001**, *75*, 5205–14, doi:10.1128/JVI.75.11.5205-5214.2001.
48. Timmins, J.; Scianimanico, S.; Schoehn, G.; Weissenhorn, W. Vesicular Release of Ebola Virus Matrix Protein VP40. *Virology* **2001**, *283*, 1–6, doi:10.1006/viro.2001.0860.
49. Hoenen, T.; Groseth, A.; Kolesnikova, L.; Theriault, S.; Ebihara, H.; Hartlieb, B.; Bamberg, S.; Feldmann, H.; Ströher, U.; Becker, S. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. *J. Virol.* **2006**, *80*, 7260–4, doi:10.1128/JVI.00051-06.
50. Reynard, O.; Nemirov, K.; Page, A.; Mateo, M.; Raoul, H.; Weissenhorn, W.; Volchkov, V.E. Conserved proline-rich region of Ebola virus matrix protein VP40 is essential for plasma membrane targeting and virus-like particle release. *J. Infect. Dis.* **2011**, *204 Suppl 3*, S884–91, doi:10.1093/infdis/jir359.
51. Martinez, O.; Johnson, J.; Manicassamy, B.; Rong, L.; Olinger, G.G.; Hensley, L.E.; Basler, C.F. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. *Cell. Microbiol.* **2010**, *12*, 148–57, doi:10.1111/j.1462-5822.2009.01385.x.
52. Tscherne, D.M.; Manicassamy, B.; Garcia-Sastre, A. An enzymatic virus-like particle assay for sensitive detection of virus entry. *J. Virol. Methods* **2010**, *163*, 336–43, doi:10.1016/j.jviromet.2009.10.020.
53. Hoenen, T.; Groseth, A.; de Kok-Mercado, F.; Kuhn, J.H.; Wahl-Jensen, V. Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. *Antiviral Res.* **2011**, *91*, 195–208, doi:10.1016/j.antiviral.2011.06.003.
54. Hoenen, T.; Feldmann, H. Reverse genetics systems as tools for the development of novel therapies against filoviruses. *Expert Rev. Anti. Infect. Ther.* **2014**, *12*, 1253–1263, doi:10.1586/14787210.2014.948848.
55. Watt, A.; Moukambi, F.; Banadyga, L.; Groseth, A.; Callison, J.; Herwig, A.; Ebihara, H.; Feldmann, H.; Hoenen, T. A Novel Life Cycle Modeling System for Ebola Virus Shows a Genome Length-Dependent Role of VP24 in Virus Infectivity. *J. Virol.* **2014**, *88*, 10511–10524, doi:10.1128/JVI.01272-14.
56. Martin, B.; Hoenen, T.; Canard, B.; Decroly, E. Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. *Antiviral Res.* **2016**, *135*, 1–14, doi:10.1016/j.antiviral.2016.09.001.
57. Bixler, S.L.; Duplantier, A.J.; Bavari, S. Discovering Drugs for the Treatment of Ebola Virus. *Curr. Treat. Options Infect. Dis.* **2017**, *9*, 299–317, doi:10.1007/s40506-017-0130-z.
58. Sweiti, H.; Ekwunife, O.; Jaschinski, T.; Lhachimi, S.K. Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. *Curr. Ther. Res.* **2017**, *84*, 10–21, doi:10.1016/j.curtheres.2017.01.007.
59. Salata, C.; Calistri, A.; Parolin, C.; Baritussio, A.; Palù, G. Antiviral activity of cationic amphiphilic drugs. *Expert Rev. Anti. Infect. Ther.* **2017**, *15*, doi:10.1080/14787210.2017.1305888.
60. Gehring, G.; Rohrmann, K.; Atenchong, N.; Mittler, E.; Becker, S.; Dahlmann, F.; Pöhlmann, S.; Vondran, F.W.R.; David, S.; Manns, M.P.; et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. *J. Antimicrob. Chemother.* **2014**, *69*, 2123–2131, doi:10.1093/jac/dku091.
61. Salata, C.; Baritussio, A.; Munegato, D.; Calistri, A.; Ha, H.R.; Bigler, L.; Fabris, F.; Parolin, C.; Palù, G.; Mirazimi, A. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. *Pathog. Dis.* **2015**, *73*, doi:10.1093/femspd/ftv032.
62. Salata, C.; Munegato, D.; Martelli, F.; Parolin, C.; Calistri, A.; Baritussio, A.; Palù, G. Amiodarone affects Ebola virus binding and entry into target cells. *New Microbiol.* **2018**, *41*.
63. Madrid, P.B.; Panchal, R.G.; Warren, T.K.; Shurtleff, A.C.; Endsley, A.N.; Green, C.E.; Kolokoltsov, A.; Davey, R.; Manger, I.D.; Gilfillan, L.; et al. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. *ACS Infect. Dis.* **2015**, *1*, 317–326, doi:10.1021/acsinfecdis.5b00030.
64. Wolf, T.; Kann, G.; Becker, S.; Stephan, C.; Brodt, H.-R.; de Leuw, P.; Grünewald, T.; Vogl, T.; Kempf, V.A.J.; Keppler, O.T.; et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. *Lancet* **2015**, *385*, 1428–1435, doi:10.1016/S0140-6736(14)62384-9.
65. Lanini, S.; Portella, G.; Vairo, F.; Kobinger, G.P.; Pesenti, A.; Langer, M.; Kabia, S.; Brogiato, G.; Amone,

- J.; Castilletti, C.; et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. *J. Clin. Invest.* **2015**, *125*, 4692–4698, doi:10.1172/JCI83111.
66. Dyall, J.; Johnson, J.C.; Hart, B.J.; Postnikova, E.; Cong, Y.; Zhou, H.; Gerhardt, D.M.; Michelotti, J.; Honko, A.N.; Kern, S.; et al. In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus. *J. Infect. Dis.* **2018**, *218*, S592–S596, doi:10.1093/infdis/jiy345.
67. Johansen, L.M.; DeWald, L.E.; Shoemaker, C.J.; Hoffstrom, B.G.; Lear-Rooney, C.M.; Stossel, A.; Nelson, E.; Delos, S.E.; Simmons, J.A.; Grenier, J.M.; et al. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. *Sci. Transl. Med.* **2015**, *7*, 290ra89–290ra89, doi:10.1126/scitranslmed.aaa5597.
68. Ren, J.; Zhao, Y.; Fry, E.E.; Stuart, D.I. Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection. *J. Med. Chem.* **2018**, *61*, 724–733, doi:10.1021/acs.jmedchem.7b01249.
69. DeWald, L.E.; Dyall, J.; Sword, J.M.; Torzewski, L.; Zhou, H.; Postnikova, E.; Kollins, E.; Alexander, I.; Gross, R.; Cong, Y.; et al. The Calcium Channel Blocker Bepridil Demonstrates Efficacy in the Murine Model of Marburg Virus Disease. *J. Infect. Dis.* **2018**, *218*, S588–S591, doi:10.1093/infdis/jiy332.
70. Beck, S.; Henß, L.; Weidner, T.; Herrmann, J.; Müller, R.; Chao, Y.-K.; Grimm, C.; Weber, C.; Sliva, K.; Schnierle, B.S. Identification of entry inhibitors of Ebola virus pseudotyped vectors from a myxobacterial compound library. *Antiviral Res.* **2016**, *132*, 85–91, doi:10.1016/j.antiviral.2016.05.017.
71. Akpovwa, H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. *Cell Biochem. Funct.* **2016**, *34*, 191–196, doi:10.1002/cbf.3182.
72. Savarino, A. Use of chloroquine in viral diseases. *Lancet Infect. Dis.* **2011**, *11*, 653–654, doi:10.1016/S1473-3099(11)70092-5.
73. Madrid, P.B.; Chopra, S.; Manger, I.D.; Gilfillan, L.; Keepers, T.R.; Shurtleff, A.C.; Green, C.E.; Iyer, L. V.; Dilks, H.H.; Davey, R.A.; et al. A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents. *PLoS One* **2013**, *8*, e60579, doi:10.1371/journal.pone.0060579.
74. Falzarano, D.; Safronetz, D.; Prescott, J.; Marzi, A.; Feldmann, F.; Feldmann, H. Lack of Protection Against Ebola Virus from Chloroquine in Mice and Hamsters. *Emerg. Infect. Dis.* **2015**, *21*, 1065–1067, doi:10.3201/eid2106.150176.
75. Dowall, S.D.; Bosworth, A.; Watson, R.; Bewley, K.; Taylor, I.; Rayner, E.; Hunter, L.; Pearson, G.; Easterbrook, L.; Pitman, J.; et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. *J. Gen. Virol.* **2015**, *96*, 3484–3492, doi:10.1099/jgv.0.000309.
76. Gignoux, E.; Azman, A.S.; de Smet, M.; Azuma, P.; Massaquoi, M.; Job, D.; Tiffany, A.; Petrucci, R.; Sterk, E.; Potet, J.; et al. Effect of Artesunate–Amodiaquine on Mortality Related to Ebola Virus Disease. *N. Engl. J. Med.* **2016**, *374*, 23–32, doi:10.1056/NEJMoa1504605.
77. Lee, N.; Shum, D.; König, A.; Kim, H.; Heo, J.; Min, S.; Lee, J.; Ko, Y.; Choi, I.; Lee, H.; et al. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system. *Antiviral Res.* **2018**, *158*, 226–237, doi:10.1016/j.antiviral.2018.08.013.
78. Henß, L.; Beck, S.; Weidner, T.; Biedenkopf, N.; Sliva, K.; Weber, C.; Becker, S.; Schnierle, B.S. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. *Virol. J.* **2016**, *13*, 149, doi:10.1186/s12985-016-0607-2.
79. Yang, S.; Xu, M.; Lee, E.M.; Gorshkov, K.; Shiryaev, S.A.; He, S.; Sun, W.; Cheng, Y.-S.; Hu, X.; Tharappel, A.M.; et al. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. *Cell Discov.* **2018**, *4*, 31, doi:10.1038/s41421-018-0034-1.
80. Kouznetsova, J.; Sun, W.; Martínez-Romero, C.; Tawa, G.; Shinn, P.; Chen, C.Z.; Schimmer, A.; Sanderson, P.; McKew, J.C.; Zheng, W.; et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. *Emerg. Microbes Infect.* **2014**, *3*, e84–e84, doi:10.1038/emi.2014.88.
81. Zhou, N.; Pan, T.; Zhang, J.; Li, Q.; Zhang, X.; Bai, C.; Huang, F.; Peng, T.; Zhang, J.; Liu, C.; et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). *J. Biol. Chem.* **2016**, *291*, 9218–9232, doi:10.1074/jbc.M116.716100.
82. Wang, Y.; Cui, R.; Li, G.; Gao, Q.; Yuan, S.; Altmeyer, R.; Zou, G. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. *Antiviral Res.* **2016**, *125*, 1–7, doi:10.1016/j.antiviral.2015.11.003.
83. Shoemaker, C.J.; Schornberg, K.L.; Delos, S.E.; Scully, C.; Pajouhesh, H.; Olinger, G.G.; Johansen, L.M.;

- White, J.M. Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection. *PLoS One* **2013**, *8*, e56265, doi:10.1371/journal.pone.0056265.
84. Bhattacharyya, S.; Warfield, K.L.; Ruthel, G.; Bavari, S.; Aman, M.J.; Hope, T.J. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. *Virology* **2010**, *401*, 18–28, doi:10.1016/j.virol.2010.02.015.
85. Daniel, J.A.; Chau, N.; Abdel-Hamid, M.K.; Hu, L.; von Kleist, L.; Whiting, A.; Krishnan, S.; Maamary, P.; Joseph, S.R.; Simpson, F.; et al. Phenothiazine-Derived Antipsychotic Drugs Inhibit Dynamin and Clathrin-Mediated Endocytosis. *Traffic* **2015**, *16*, 635–654, doi:10.1111/tra.12272.
86. Cheng, H.; Lear-Rooney, C.M.; Johansen, L.; Varhegyi, E.; Chen, Z.W.; Olinger, G.G.; Rong, L. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. *J. Virol.* **2015**, *89*, 9932–9938, doi:10.1128/JVI.01337-15.
87. Schafer, A.; Cheng, H.; Xiong, R.; Soloveva, V.; Retterer, C.; Mo, F.; Bavari, S.; Thatcher, G.; Rong, L. Repurposing potential of 1st generation H₁-specific antihistamines as anti-filovirus therapeutics. *Antiviral Res.* **2018**, *157*, 47–56, doi:10.1016/j.antiviral.2018.07.003.
88. Cheng, H.; Schafer, A.; Soloveva, V.; Gharaibeh, D.; Kenny, T.; Retterer, C.; Zamani, R.; Bavari, S.; Peet, N.P.; Rong, L. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor. *Antiviral Res.* **2017**, *145*, 24–32, doi:10.1016/j.antiviral.2017.06.015.
89. Johansen, L.M.; Brannan, J.M.; Delos, S.E.; Shoemaker, C.J.; Stossel, A.; Lear, C.; Hoffstrom, B.G.; DeWald, L.E.; Schornberg, K.L.; Scully, C.; et al. FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection. *Sci. Transl. Med.* **2013**, *5*, 190ra79–190ra79, doi:10.1126/scitranslmed.3005471.
90. Zhao, Y.; Ren, J.; Harlos, K.; Jones, D.M.; Zeltina, A.; Bowden, T.A.; Padilla-Parra, S.; Fry, E.E.; Stuart, D.I. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. *Nature* **2016**, *535*, 169–172, doi:10.1038/nature18615.
91. Fan, H.; Du, X.; Zhang, J.; Zheng, H.; Lu, X.; Wu, Q.; Li, H.; Wang, H.; Shi, Y.; Gao, G.; et al. Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. *Sci. Rep.* **2017**, *7*, 41226, doi:10.1038/srep41226.
92. Nelson, E.; Barnes, A.; Wiehle, R.; Fontenot, G.; Hoenen, T.; White, J. Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications. *Viruses* **2016**, *8*, 206, doi:10.3390/v8080206.
93. Bekerman, E.; Einav, S. Combating emerging viral threats. *Science (80-)*. **2015**, *348*, 282–283, doi:10.1126/science.aaa3778.
94. Garcia, M.; Cooper, A.; Shi, W.; Bornmann, W.; Carrion, R.; Kalman, D.; Nabel, G.J. Productive Replication of Ebola Virus Is Regulated by the c-Abl1 Tyrosine Kinase. *Sci. Transl. Med.* **2012**, *4*, 123ra24–123ra24, doi:10.1126/scitranslmed.3003500.
95. Bekerman, E.; Neveu, G.; Shulla, A.; Brannan, J.; Pu, S.-Y.; Wang, S.; Xiao, F.; Barouch-Bentov, R.; Bakken, R.R.; Mateo, R.; et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. *J. Clin. Invest.* **2017**, *127*, 1338–1352, doi:10.1172/JCI89857.
96. Nelson, E.A.; Dyal, J.; Hoenen, T.; Barnes, A.B.; Zhou, H.; Liang, J.Y.; Michelotti, J.; Dewey, W.H.; DeWald, L.E.; Bennett, R.S.; et al. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. *PLoS Negl. Trop. Dis.* **2017**, *11*, e0005540, doi:10.1371/journal.pntd.0005540.
97. Johnson, J.C.; Martinez, O.; Honko, A.N.; Hensley, L.E.; Olinger, G.G.; Basler, C.F. Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. *Antiviral Res.* **2014**, *107*, 102–109, doi:10.1016/j.antiviral.2014.04.014.
98. Neveu, G.; Ziv-Av, A.; Barouch-Bentov, R.; Berkerman, E.; Mulholland, J.; Einav, S. AP-2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets. *J. Virol.* **2015**, *89*, 4387–4404, doi:10.1128/JVI.02705-14.
99. Pu, S.-Y.; Wouters, R.; Schor, S.; Rozenski, J.; Barouch-Bentov, R.; Prugar, L.I.; O'Brien, C.M.; Brannan, J.M.; Dye, J.M.; Herdewijn, P.; et al. Optimization of Isothiazolo[4,3-*b*]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity. *J. Med. Chem.* **2018**, *61*, 6178–6192, doi:10.1021/acs.jmedchem.8b00613.
100. Moeschler, S.; Locher, S.; Zimmer, G. 1-Benzyl-3-cetyl-2-methylimidazolium Iodide (NH125) Is a Broad-Spectrum Inhibitor of Virus Entry with Lysosomotropic Features. *Viruses* **2018**, *10*, 306, doi:10.3390/v10060306.
101. Basu, A.; Li, B.; Mills, D.M.; Panchal, R.G.; Cardinale, S.C.; Butler, M.M.; Peet, N.P.; Majgier-Baranowska, H.; Williams, J.D.; Patel, I.; et al. Identification of a Small-Molecule Entry Inhibitor for Filoviruses. *J. Virol.* **2011**, *85*, 3106–3119, doi:10.1128/JVI.01456-10.
102. Basu, A.; Mills, D.M.; Mitchell, D.; Ndungo, E.; Williams, J.D.; Herbert, A.S.; Dye, J.M.; Moir, D.T.;

- Chandran, K.; Patterson, J.L.; et al. Novel Small Molecule Entry Inhibitors of Ebola Virus. *J. Infect. Dis.* **2015**, *212*, S425–S434, doi:10.1093/infdis/jiv223.
103. Anantpadma, M.; Kouznetsova, J.; Wang, H.; Huang, R.; Kolokoltsov, A.; Guha, R.; Lindstrom, A.R.; Shtanko, O.; Simeonov, A.; Maloney, D.J.; et al. Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors. *Antimicrob. Agents Chemother.* **2016**, *60*, 4471–4481, doi:10.1128/AAC.00543-16.
104. Zhang, X.; Liu, Q.; Zhang, N.; Li, Q.; Liu, Z.; Li, Y.; Gao, L.; Wang, Y.; Deng, H.; Song, D. Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage. *Eur. J. Med. Chem.* **2018**, *149*, 45–55, doi:10.1016/j.ejmech.2018.02.061.
105. Cui, Q.; Du, R.; Anantpadma, M.; Schafer, A.; Hou, L.; Tian, J.; Davey, R.; Cheng, H.; Rong, L. Identification of Ellagic Acid from Plant *Rhodiola rosea* L. as an Anti-Ebola Virus Entry Inhibitor. *Viruses* **2018**, *10*, 152, doi:10.3390/v10040152.
106. Shtanko, O.; Sakurai, Y.; Reyes, A.N.; Noël, R.; Cintrat, J.-C.; Gillet, D.; Barbier, J.; Davey, R.A. Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection. *Antiviral Res.* **2018**, *149*, 154–163, doi:10.1016/j.antiviral.2017.11.016.
107. Lindstrom, A.; Anantpadma, M.; Baker, L.; Raghavendra, N.M.; Davey, R.; Davisson, V.J. Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H⁺)-ATPase Inhibition. *ChemMedChem* **2018**, *13*, 2664–2676, doi:10.1002/cmdc.201800587.
108. van der Linden, W.A.; Schulze, C.J.; Herbert, A.S.; Krause, T.B.; Wirchnianski, A.A.; Dye, J.M.; Chandran, K.; Bogoyo, M. Cysteine Cathepsin Inhibitors as Anti-Ebola Agents. *ACS Infect. Dis.* **2016**, *2*, 173–179, doi:10.1021/acsinfecdis.5b00130.
109. Cui, Q.; Cheng, H.; Xiong, R.; Zhang, G.; Du, R.; Anantpadma, M.; Davey, R.; Rong, L. Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. *Viruses* **2018**, *10*, 678, doi:10.3390/v10120678.
110. Miller, E.H.; Harrison, J.S.; Radoshitzky, S.R.; Higgins, C.D.; Chi, X.; Dong, L.; Kuhn, J.H.; Bavari, S.; Lai, J.R.; Chandran, K. Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes. *J. Biol. Chem.* **2011**, *286*, 15854–15861, doi:10.1074/jbc.M110.207084.
111. Li, Q.; Ma, L.; Yi, D.; Wang, H.; Wang, J.; Zhang, Y.; Guo, Y.; Li, X.; Zhou, J.; Shi, Y.; et al. Novel cyclopeptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein. *Antiviral Res.* **2018**, *155*, 1–11, doi:10.1016/j.antiviral.2018.04.020.